CARs mediate tumor surface-associated antigen recognition in the major histocompatibility complex (MHC)-unrestricted manner, activate T lymphocytes, and cause tumor killing (Figure 1) (Eshhar et al., 1993; Feins et al., 2019). The gene discussed is HLA-C; the disease is neoplasm.